Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction
Sponsor: Mayo Clinic
Summary
The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.
Official title: Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride for Postoperative Analgesia After Breast Reduction Surgery: A Prospective, Single Blind, Non-randomized Controlled Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2024-01-24
Completion Date
2025-10-06
Last Updated
2026-10-29
Healthy Volunteers
Yes
Conditions
Interventions
Bupivacaine Hydrochloride
20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast
Liposomal Bupivacaine
20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast
Locations (1)
Mayo Clinic Minnesota
Rochester, Minnesota, United States